Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitami… Read more
Sunny Pharmtech Inc. (6676) - Total Assets
Latest total assets as of June 2025: NT$1.49 Billion TWD
Based on the latest financial reports, Sunny Pharmtech Inc. (6676) holds total assets worth NT$1.49 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sunny Pharmtech Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Sunny Pharmtech Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sunny Pharmtech Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Sunny Pharmtech Inc.'s total assets of NT$1.49 Billion consist of 23.0% current assets and 77.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.7% |
| Accounts Receivable | NT$50.67 Million | 3.2% |
| Inventory | NT$123.49 Million | 7.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$35.96 Million | 2.3% |
| Goodwill | NT$25.24 Million | 1.6% |
Asset Composition Trend (2019–2024)
This chart illustrates how Sunny Pharmtech Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunny Pharmtech Inc.'s current assets represent 23.0% of total assets in 2024, a decrease from 32.1% in 2019.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2024, down from 18.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 5.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 7.8% of total assets.
Sunny Pharmtech Inc. Competitors by Total Assets
Key competitors of Sunny Pharmtech Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sunny Pharmtech Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sunny Pharmtech Inc. generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sunny Pharmtech Inc. is currently not profitable relative to its asset base.
Sunny Pharmtech Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 3.24 | 3.50 |
| Quick Ratio | 0.74 | 2.55 | 2.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$75.20 Million | NT$ 300.55 Million | NT$ 345.69 Million |
Sunny Pharmtech Inc. - Advanced Valuation Insights
This section examines the relationship between Sunny Pharmtech Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.24 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | NT$1.59 Billion |
| Market Capitalization | $50.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sunny Pharmtech Inc.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sunny Pharmtech Inc.'s assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sunny Pharmtech Inc. (2019–2024)
The table below shows the annual total assets of Sunny Pharmtech Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.59 Billion | -7.30% |
| 2023-12-31 | NT$1.71 Billion | +5.08% |
| 2022-12-31 | NT$1.63 Billion | +2.19% |
| 2021-12-31 | NT$1.59 Billion | +6.34% |
| 2020-12-31 | NT$1.50 Billion | -7.32% |
| 2019-12-31 | NT$1.62 Billion | -- |